PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

1

(Use as many sheets as necessary)

Sheet of 1

Complete if Known				
Application Number	10/826,743-Conf. #1363			
Filing Date	April 16, 2004			
First Named Inventor	Suanne Nakajima			
Art Unit	N/A /62 4			
Examiner Name	Not Yet Assigned KIFLE			
Attorney Docket Number	60583(50530)			

U.S. PATENT DOCUMENTS					
Examiner Cite No.1	Cita	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where
		Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear
13:16.		6,608,027	8-19-2003	Tsantrizos et al.	
A.K.		US 2002/0037998 A1	3-28-02	Llinas-Brunet et al.	
D.K.		6,329,379	12-2001	Llinas-Brunet et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Cit Initiats*	Cita	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	П
	No.1	Country Code ³ -Number ^A -Kind Code ⁵ (if known)				Τ ⁶
B.K.	ВА	WO-00/09543	02-24-2000	Boehringer Ingelheim (Canada) Ltd.		
1.16.	BB	WO-00/59929	10-12-2000	Boehringer Ingelheim (Canada) Ltd.	:	
A.K.	ВС	WO-2003/053349-A3	07-03-2003	Bristol-Myers Squibb Company		
A.K.	BD	WO-2004/072243-A2	08-26-2004	Enanta Pharmaceuticals, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (MPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
B.K.	CA	M. Llinàs-Brunet, et al., "Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease," Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1713-1718.		
D.K.	СВ	A. Spatola, "Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates, Conformational Constraints, and Rela," Department of Chemistry, University of Louisville, Louisville Kentucky, pp. 267-357, XP 002032461.		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BOS2_493810.1

Examiner // /	1 2/1/	Date	1/24/25
Signature /		Considered	6/4/05
			7

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.